IP Library Granted Patent US 11,464,757
Granted Patent B2
US 11,464,757 · App. 17/148,409 · Granted Oct 11, 2022

Compositions and methods for lowering triglycerides

Inventors: Ian Osterloh (Kent, GB); Pierre Wicker (Mystic, CT); Rene Braeckman (Richboro, PA); Paresh Soni (Mystic, CT); Mehar Manku (Birmingham, GB)
Assignee: Amarin Pharmaceuticals Ireland Limited
A61K31/232A61K9/48A61K31/202A61K31/366A61K31/40A61K31/505A61P3/06A61P9/10C07C57/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,464,757
App. No.
17/148,409
Granted
Oct 11, 2022
Kind
B2
Abstract

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Claims (10)

1. A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising administering to the subject a composition comprising about 1 g to about 4 g of eicosapentaenoic acid and docosahexaenoic acid in free acid form per day for a period effective to reduce fasting triglycerides in the subject wherein the composition comprises at least 96% by weight eicosapentaenoic acid.

2. The method of claim 1 , wherein the subject has serum LDL-C levels of about 40 mg/dl to about 115 mg/dl.

3. The method of claim 1 , wherein the composition is administered to the subject 1 to 4 times per day.

4. The method of claim 3 , wherein the composition is present in one or more capsules.

5. The method of claim 4 , wherein 2 g of the composition is administered to the subject per day and each of said one or more capsules contains about 800 mg to about 1200 mg of eicosapentaenoic acid.

6. The method of claim 5 , wherein each of said one or more capsules contains not more than about 4%, by weight, of any individual fatty acid selected from docosahexanoic acid, linolenic acid, alpha-linolenic acid, stearidonic acid, eicosatrienoic acid and docosapentaenoic acid.

7. The method of claim 1 wherein the period effective to reduce fasting triglycerides is about 1 week to about 15 weeks.

8. The method of claim 7 , wherein the period effective to reduce fasting triglycerides is about 1 week to about 12 weeks.

9. The method of claim 8 , wherein the period effective to reduce fasting triglycerides is about 1 week to about 5 weeks.

10. The method of claim 1 , wherein the subject exhibits an increase in serum EPA and DHA at the end of said period effective to reduce fasting triglycerides.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2026
From: AMARIN PHARMA, INC.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 074091/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2026
From: OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH; MANKU, MEHAR
To: AMARIN PHARMA, INC.
Reel/Frame 074071/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2021
From: OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH; MANKU, MEHAR; AMARIN PHARMA, INC.
To: AMARIN PHARMA, INC.; AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 055514/0911 →